
10-week, but not 7-week, Dapagliflozin Treatment Improves Severe Renal Impairment in the Uni-nephrectomized SDT fatty rat, a 10-week Model of Advanced Renal Complications and Glomerular Filtration Rate Decline.
Key Word:
Dapagliflozin(ダパグリフロジン)、Renal Impairment(腎障害)、Uni-nephrectomized(片腎摘出)、Renal Complications(腎合併症)、Glomerular Filtration Rate(糸球体濾過速度(GFR))、hypertensive, obese, type 2 diabetic model(高血圧、肥満、2型糖尿病モデル)
François Briand1, Masami Shinohara2, Emmanuel Brousseau1, Takeshi Ohta3, Yasushi Kageyama2, Thierry Sulpice1
1Physiogenex, Labège, France; 2CLEA Japan Inc. Meguro-ku, Tokyo, Japan, 3Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan
For more details, please click here (Google Search)
- ISN-WCN 2017: Centro Banamex in, Mexico City, Mexico.
- April 21-25, 2017
Related CLEA Japan product: SDT fatty/Jcl
For the animal model, please click here ▼
https://www.clea-japan.com/en/products/diabetes/item_a0150
https://www.clea-japan.com/products/diabetes/item_a0150
Inquiry(お問い合わせ)
If you have any questions, please feel free to contact us.